Ixabepilone for the treatment of taxane-refractory breast cancer

Future Oncology

Volumn 4, Issue 3, 2008, Pages 333-340

  Moulder, Stacy L ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

BMS 247550; Breast cancer; Chemotherapy; Ixabepilone; Metastatic

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BETA TUBULIN; CAPECITABINE; CREMOPHOR; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; IXABEPILONE; IXEMPRA; TAXANE DERIVATIVE; TRASTUZUMAB; ZK EPO;

ADJUVANT THERAPY; ADVANCED CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HUMAN; INFECTION; METASTASIS; MICROTUBULE ASSEMBLY; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; UNITED STATES;

ANIMALS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; HUMANS; TAXOIDS;

EID: 47249087285     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.3.333     Document Type: Review

References (39)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005).
2. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM: Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97(3), 545-553 (2003).
3. Clark GM, Sledge GW Jr, Osborne CK, McGuire WL: Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J. Clin. Oncol. 5(1), 55-61 (1987).
4. Nabholtz JM, Senn HJ, Bewoda WR et al.: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous andiracycline-containing chemotherapy. 304 Study Group. J. Clin. Oncol. 17(5), 1413-1424 (1999).
5. Bishop JF, Dewar J, Toner GC et al.: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as frontline therapy in untreated metastatic breast cancer. J. Clin. Oncol. 17 (8), 2355-2364 (1999).
6. Sledge GW, Neuberg D, Bernardo P et al.: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (EI 193). J. Clin. Oncol. 21(4), 588-592 (2003).
7. Chan S, Friedrichs K, Noel D et al.: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 17(8), 2341-2354 (1999).
8. Jones SE, Erban J, Overmoyer B et al.: Randomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 23(24), 5542-5551 (2005).
9. Gradishar WJ, Tjulandin S, Davidson N et al.: Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: results of a Phase III trial. J. Clin. Oncol. 23 (31), 7794-7803 (2005).
10. O'Shaughnessy J, Nag S, Calderill-Ruiz G et al.: Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC), interim results of a global Phase III study. Proc. Am. Soc. Clin. Oncol. 22(7) (2003) (Abstract 25).
11. Sjostrom J, Blomqvist C, Mouridsen H et al.: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised Phase III study wito crossover on progression by the Scandinavian Breast Group. Eur. J. Cancer 35(8), 1194-1201 (1999).
12. O'Shaughnessy J, Miles D, Vukelja S et al.: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J. Clin. Oncol. 20(12), 2812-2823 (2002).
13. Bonneterre J, Roche H, Monnier A et al.: Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br. J. Cancer 87(11), 1210-1215 (2002).
14. Seidman AD, O'Shaughnessy J, Misset JL: Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 7 (Suppl. 6), 20-28 (2002).
15. Talbot DC, Moiseyenko V, van Belle S et al.: Randomised, Phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br. J. Cancer 86(9), 1367-1372 (2002).
16. Desai A, Mitchison TJ: Microtubule polymerization dynamics. Annu. Rev. Cell Dev. Biol. 13, 83-117 (1997).
17. Larkin JM, Kaye SB: Epothilones in the treatment of cancer. Expert Opin. Invest. Drugs 15(6), 691-702 (2006).
18. Belotti D, Vergani V, Drudis T et al.: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2(11), 1843-1849 (1996).
19. Miller ML, Ojima I: Chemistry and chemical biology of taxane anticancer agents. Chem. Rec. 1(3), 195-211 (2001).
20. Had M, Loganzo F, Annable T et al.: Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules. Mol. Cancer Ther. 5(2), 270-278 (2006).
21. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH: The binding mode of epothilone A on α, β-tubulin by electron crystallography. Science 305(5685), 866-869 (2004).
22. Lee FY, Borzilleri R, Fairchild CR et al.: BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 7(5), 1429-1437 (2001).
23. Bollag DM, McQueney PA, Zhu J et al.: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55(11), 2325-2333 (1995).
24. Aghajanian C, Burris HA 3rd, Jones S et al.: Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J. Clin. Oncol. 25(9), 1082-1088 (2007).
25. Mani S, McDaid H, Hamilton A et al.: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res. 10(4), 1289-1298 (2004).
26. Gadgeel SM, Wozniak A, Boinpally RR et al.: Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin. Cancer Res. 11(17), 6233-6239 (2005).
27. Zhuang SH, Agrawal M, Edgerly M et al.: A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 103(9), 1932-1938 (2005).
28. Abraham J, Agrawai M, Bakke S et al.: Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J. Clin. Oncol. 21(9), 1866-1873 (2003).
29. Dickson N, Peck R, Wu C, Burris H: Ixabepilone given weekly in patients with advanced malignancies: final efficacy and safety results of a Phase I trial. J. Clin. Oncol. 24(S18) (2006) (Abstract 2040).
30. Takimoto CH, Liu PY, Lenz H et al.: A Phase I pharmacokinetic (PK) study of the epothilone B analogue, ixabepilone (BMS-247550) in patients (pts) with advanced malignancies and varying degrees of hepatic impairment. A SWOG Early Therapeutics Commitee and NCI Organ Dysfunction Working Group Trial. J. Clin. Oncol. 24(S18) (2006) (Abstract 2004).
31. Perez EA, Lerzo G, Pivot X et al.: Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 25(23), 3407-3414 (2007).
32. Thomas E, Tabernero J, Fornier M et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol. 25(23), 3399-3406 (2007).
33. Low JA, Wedam SB, Lee JJ et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J. Clin. Oncol. 23(12), 2726-2734 (2005).
34. Roche H, Yelle L, Cognetti F et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol. 25(23), 3415-3420 (2007).
35. Denduluri N, Low JA, Lee JJ et al.: Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J. Clin. Oncol. 25(23), 3421-3427 (2007).
36. Baselga J, Gianni L, Llombart A et al.: Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2005 (Abstract 305).
37. Bunnell C, Klimovsky J, Thomas E: Final efficacy results of a Phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and anthracycline. J. Clin. Oncol. 24(S18) (2006) (Abstract 10511).
38. Thomas ES, Gomez HL, Li RK et al.: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 25(33), 5210-5217 (2007).
39. +) metastatic breast cancer (MBC). A trial coordinated by the Eastern Cooperative Oncology Group (E2103). 42nd ASCO Annual Meeting. Atlanta, GA, USA, 2-6 June, 2006 (Abstract 152).